The progress of immunotherapy for glioblastoma

Figures & data

Table 1. Survival of EGFRvIII positive adult patient with GBM in 3 Phase II Rindopepimut trials

Trial	PFS(month)	OS(month)
ACT III (n=65)	12.3	24.6
ACT II (n=22)	15.2	23.6
ACTIVATE (n=18)	14.2	26

Table 2. Main DCs-based Phase II, III clinical trials

Vaccine type	Phase	Experimental design	References
DCVax-Brain	III	2/3 vaccine, 1/3 placebo with option of crossover at disease progression	NCT00045968
Tumor lysate vaccine	II	Vaccine + standard therapy versus standard therapy alone	NCT01213407
Tumor lysate vaccine	II	DCs treated with PGE2 and TNF-, cervical lymph node injection	NCT00323115
Cancer stem cell vaccine, ICT-107	II	Six synthetic peptides associated with CSCs loaded onto autologous DCs	NCT01280552
Cancer stem cell vaccine	II	Autologous DCs loaded with stem cell-like antigens from irradiated GBM vs. placebo	NCT01567202
Alpha type I DC peptide vaccine	I/II	Four peptides loaded onto α type I DCs + poly-ICLC, included GBM and anaplastic glioma	NCT00766753

Table 3. Clinical trials of adoptive immunotherapy of CNS tumor

Tumor type	Phase	Note	References
GBM	I	CMV-activated T cells alone or combined with a DC-based vaccine	NCT00693095
Malignant glioma	I	Autologous CD8+ T cells expressing inducible suicide fusion protein and an IL-13 chimeric immunoreceptor	NCT00693095
Medulloblastoma And PNET	I/II	Tumor-specific T cells alone or combined with a DC-based vaccine	NCT01326104